153 related articles for article (PubMed ID: 38390262)
1. Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors.
Wang J; Guo H; Yang J; Mao J; Wang Y; Yan X; Guo H
Front Oncol; 2024; 14():1339729. PubMed ID: 38390262
[TBL] [Abstract][Full Text] [Related]
2. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
PeerJ; 2022; 10():e14566. PubMed ID: 36540802
[TBL] [Abstract][Full Text] [Related]
3. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
5. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors.
Yan X; Wang J; Mao J; Wang Y; Wang X; Yang M; Qiao H
Front Nutr; 2023; 10():1213255. PubMed ID: 37575320
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
Kazandjian D; Gong Y; Keegan P; Pazdur R; Blumenthal GM
JAMA Oncol; 2019 Oct; 5(10):1481-1485. PubMed ID: 31343662
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study.
Li X; Lu D; Zhang Z; Zhang Y; Wang J; Hu Y
J Thorac Dis; 2022 Oct; 14(10):4125-4135. PubMed ID: 36389301
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
Front Oncol; 2020; 10():572853. PubMed ID: 33163403
[TBL] [Abstract][Full Text] [Related]
12. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
13. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
14. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
Front Oncol; 2021; 11():697865. PubMed ID: 34692478
[TBL] [Abstract][Full Text] [Related]
16. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
Front Oncol; 2021; 11():690093. PubMed ID: 34150659
[TBL] [Abstract][Full Text] [Related]
17. Nutritional status as prognostic factor of advanced oesophageal cancer patients treated with immune checkpoint inhibitors.
Chen N; Yu Y; Shen W; Xu X; Fan Y
Clin Nutr; 2024 Jan; 43(1):142-153. PubMed ID: 38043419
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.
Chen S; Guo S; Gou M; Pan Y; Fan M; Zhang N; Tan Z; Dai G
Front Oncol; 2022; 12():951985. PubMed ID: 36387152
[TBL] [Abstract][Full Text] [Related]
20. Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes.
Chen L; Sun H; Zhao R; Huang R; Pan H; Zuo Y; Zhang L; Xue Y; Song H; Li X
Front Pharmacol; 2022; 13():836958. PubMed ID: 35308215
[No Abstract] [Full Text] [Related]
[Next] [New Search]